Brought to you by 
Lexicon Genetics and Organon in drug development agreement
20 May 2005
Executive Summary
Drug discovery company Lexicon Genetics (gene knockout technology) and NV Organon, the human health care business of Akzo Nobel, have agreed to jointly discover and develop at least five therapeutic antibodies and secreted proteins, initially focusing on inflammatory disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lexicon Genetics and Organon in drug development agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice